Early Escalation to Vancomycin in Severe Pediatric Pneumonia With Pleural Effusion: A Case Report

Community-acquired pneumonia (CAP) is a significant cause of pediatric morbidity and mortality. While beta-lactams and macrolides are standard treatments, severe cases caused by multidrug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), necessitate early escalation to vancomycin. This report emphasizes the importance of clinical judgment, early identification of resistance, and timely intervention in the management of severe pediatric pneumonia. A two-year-old female presented with fever, cough, and progressive respiratory symptoms. Chest X-ray revealed left lung consolidation, bilateral opacities, and blunting of the left costophrenic angle. Blood cultures were negative, and sputum cultures could not be obtained. Initial therapy with ceftriaxone and clarithromycin failed to achieve clinical improvement. Vancomycin was initiated and monitored with therapeutic trough levels. The patient showed significant clinical improvement with vancomycin, evidenced by CRP trends and resolution of pleural effusion on imaging. This case highlights the importance of early identification of antibiotic resistance, therapeutic drug monitoring for vancomycin, and the role of imaging in guiding management decisions. The absence of microbiological confirmation emphasized the critical need for clinical judgment. Vancomycin remains a fundamental therapy for resistant pathogens like MRSA. Timely treatment, imaging, and careful monitoring can significantly improve outcomes in severe pediatric pneumonia.